Phase 1 N=20 Ketogenic Diet for Recurrent Glioblastoma
Recurrent Glioblastoma
Primary: Applicability as Measured by Discontinuation of Study Treatment Due to Intolerability — 15 percent of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=17 Effects of Vortioxetine (Lu AA21004) on the Concentrations of Selected Neurotransmitters in Healthy Male Adults
Healthy
Primary: Area Under the Effect Curve From Time Zero to 24 Hours Postdose of 5-hydroxytryptamine (5-HT) in Plasma — 4183024; 3854399; 4224058; 3912292 pg*hr/mL
Phase 1 N=188 A Study to Investigate the Safety and Tolerability of MK-0517 in Healthy Subjects (MK-0517-012)
Chemotherapy-Induced Nausea and Vomiting · Postoperative Nausea and Vomiting
Primary: Area Under the Plasma-Time Curve (AUC[0 to Infinity]) for Aprepitant and MK-0517 for Study Part V — 29215; 24961; 31724 ng*hr/mL
Phase 1 N=29 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single-Dose Subcutaneous Administration of MEDI-528
Healthy
Primary: Incidence of Adverse Events — 5; 4; 6; 6 Participants
Phase 1 N=30 Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer
Pancreatic Cancer
Primary: Percent of Patients Experiencing an Unacceptable Toxicity — 6.67; 6.67 Percentage of Participants
Phase 1 N=22 Drug Interaction Study With Rifampicin and Afatinib
Healthy
Primary: Area Under Curve From 0 to Infinity Hours (AUC0-∞) — 912; 610 ng*h/mL
Phase 1 N=39 A Study of JNJ-30979754 (Decitabine) in Patients With Myelodysplastic Syndrome
Myelodysplastic Syndrome
Primary: Phase II: Overall Remission Rate (ORR): Number of Participants Who Achieved Complete Remission (CR)+Partial Remission (PR) - as Per International Working Group (IWG)…
Phase 1 N=31 Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Women With Advanced Breast Cancer
Advanced Breast Cancer
Primary: Number of Participants With Dose Limiting Toxicities Per Dose Level - Safety Population — 1; 1; 1; 2 participants
Phase 1 N=21 Sildenafil in Single Ventricle Patients
Heart Disease
Primary: Maximum Sildenafil Plasma Concentration — 181; 515; 545; 202 ng/mL
Phase 1 N=20 Gut Microbial Transplantation in Pediatric Inflammatory Bowel Diseases
Inflammatory Bowel Disease (IBD)
Primary: Clinical Response — 9 Participants — p=0.03
Phase 1 N=25 Evaluation of Continuous Glucose Monitoring in Participants With Type 2 Diabetes Mellitus (MK-0000-258 AM2)
Type 2 Diabetes Mellitus
Primary: 24 Hour Weighted Mean Glucose (WMG) At 2 Weeks — 126.9; 114.2 mg/dL
Phase 1 N=99 A Study of JNJ-26866138 (Bortezomib) in Untreated Multiple Myeloma Patients Who Are Not Candidates for Hematopoietic Stem Cell Transplant (HSCT)
Multiple Myeloma
Primary: Number of Participants With Dose Limiting Toxicity During the Phase I (Cycle 1) — 0; 0; 1 Participants
Phase 1 N=56 A Study of LY110140 in Healthy Japanese Male Participants
Healthy Volunteer
Primary: Number of Participants With One or More Drug-Related Adverse Events (AEs) or Any Serious AEs During the Single-Dose (SD) Period — 0; 0; 0; 0 participants
Phase 1 N=16 MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies
Advanced Solid Tumors · Tumors · Cancer
Primary: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose of MK-2206 Administered Weekly in Combination With Weekly Paclitaxel 80 mg/m^2 and Trastuzumab 2 mg/m^2 — 135 mg
Phase 1 N=64 Safety and Tolerability of AGN-199201 in Patients With Erythema Associated With Rosacea
Rosacea · Erythema
Primary: Percentage of Responders With at Least a 2-Grade Decrease From Baseline in Both Clinician Erythema Assessment (CEA) and Subject's Self Assessment (SSA) at Day 1 — 15.6…